Log in

Viela Bio Stock Forecast, Price & News

+0.38 (+0.97 %)
(As of 12/4/2020 12:00 AM ET)
Today's Range
Now: $39.75
50-Day Range
MA: $34.85
52-Week Range
Now: $39.75
Volume371,470 shs
Average Volume214,936 shs
Market Capitalization$2.18 billion
P/E RatioN/A
Dividend YieldN/A
Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.25 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



Market Cap$2.18 billion
Next Earnings DateN/A
OptionableNot Optionable
+0.38 (+0.97 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VIE News and Ratings via Email

Sign-up to receive the latest news and ratings for VIE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Viela Bio (NYSE:VIE) Frequently Asked Questions

How has Viela Bio's stock been impacted by COVID-19 (Coronavirus)?

Viela Bio's stock was trading at $53.88 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VIE shares have decreased by 26.2% and is now trading at $39.75.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Viela Bio?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viela Bio in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Viela Bio
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Viela Bio?

Wall Street analysts have given Viela Bio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Viela Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Viela Bio's earnings last quarter?

Viela Bio, Inc. (NYSE:VIE) posted its earnings results on Sunday, November, 15th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.07. The company had revenue of $2.32 million for the quarter, compared to analyst estimates of $4.10 million.
View Viela Bio's earnings history

What price target have analysts set for VIE?

7 Wall Street analysts have issued 12-month price objectives for Viela Bio's shares. Their forecasts range from $48.00 to $78.00. On average, they expect Viela Bio's stock price to reach $57.86 in the next year. This suggests a possible upside of 45.6% from the stock's current price.
View analysts' price targets for Viela Bio

Who are some of Viela Bio's key competitors?

What other stocks do shareholders of Viela Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viela Bio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Taiwan Semiconductor Manufacturing (TSM), Square (SQ), AbbVie (ABBV), Cisco Systems (CSCO), DocuSign (DOCU), Telefonaktiebolaget LM Ericsson (publ) (ERIC), Intel (INTC) and JD.com (JD).

Who are Viela Bio's key executives?

Viela Bio's management team includes the following people:
  • Dr. Zhengbin Yao, Chairman, Pres & CEO (Age 54, Pay $846.75k)
  • Mr. Mitchell Chan, Chief Financial Officer (Age 39, Pay $420.34k)
  • Dr. Aaron Ren M.B.A., Ph.D., Sr. VP & Head of Bus. Devel. and Operations (Age 43, Pay $385.63k)
  • Dr. Jörn Drappa M.D., Ph.D., Chief Medical Officer and Head of R&D (Age 55, Pay $637.39k)
  • Mr. James Paul Kastenmayer J.D., Ph.D., Gen. Counsel & Company Sec. (Age 48)
  • Ms. Kate Surdez, Sr. VP & Head of HR
  • Ms. Rachel Ettinger, Sr. Director & Head of Research
  • Mr. Bill Rees, Sr. Director & Head of Translational Science
  • Mr. Ted Phillips, VP & Head of Clinical Operations
  • Mr. Dewei She, Sr. Director and Head of Biostatistics, Data Management, & Programming

When did Viela Bio IPO?

(VIE) raised $150 million in an initial public offering on Thursday, October 3rd 2019. The company issued 7,500,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and Cowen served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is Viela Bio's stock symbol?

Viela Bio trades on the New York Stock Exchange (NYSE) under the ticker symbol "VIE."

Who are Viela Bio's major shareholders?

Viela Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.37%), JPMorgan Chase & Co. (2.16%), State Street Corp (2.15%), ArrowMark Colorado Holdings LLC (0.61%), Charles Schwab Investment Management Inc. (0.22%) and Morgan Stanley (0.15%). Company insiders that own Viela Bio stock include Meadow Ltd Boundless, Plc Astrazeneca and Xiaomeng Tong.
View institutional ownership trends for Viela Bio

Which institutional investors are selling Viela Bio stock?

VIE stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Wells Fargo & Company MN, Alps Advisors Inc., Alps Advisors Inc., and Virtus ETF Advisers LLC.
View insider buying and selling activity for Viela Bio

Which institutional investors are buying Viela Bio stock?

VIE stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, JPMorgan Chase & Co., BlackRock Inc., Morgan Stanley, Charles Schwab Investment Management Inc., Jane Street Group LLC, Squarepoint Ops LLC, and California Public Employees Retirement System. Company insiders that have bought Viela Bio stock in the last two years include Plc Astrazeneca, and Xiaomeng Tong.
View insider buying and selling activity for Viela Bio

How do I buy shares of Viela Bio?

Shares of VIE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Viela Bio's stock price today?

One share of VIE stock can currently be purchased for approximately $39.75.

How big of a company is Viela Bio?

Viela Bio has a market capitalization of $2.18 billion. Viela Bio employs 139 workers across the globe.

What is Viela Bio's official website?

The official website for Viela Bio is www.vielabio.com.

How can I contact Viela Bio?

The company can be reached via phone at 240-558-0038.

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.